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CObjective: Texas House Bill 790 resulted in the expansion of the new-
born screening panel from 7 disorders to 27 disorders. Implementation
of this change began in 2007. The objective of this study was to estimate
the incremental cost-effectiveness of the expanded newborn screening
program compared with the previous standard screening in Texas.
Methods: A Markov model (for a hypothetical cohort of Texas births in
2007) was constructed to compare lifetime costs and quality-adjusted
life-years (QALYs) between the expanded newborn screening and pre-
expansion newborn screening. Estimates of costs, probabilities of se-
quelae, and utilities for disorder categories were obtained from a com-
bination of Texas statistics, the literature, and expert opinion. A
baseline discount rate of 3% was used for both costs and QALYs, with a
range of 0% to 5%. Analyses were conducted from a payer’s perspective,
and so only direct medical cost estimates were included. Results: The O
ad, E
rsity
al So
oi:10.1016/j.jval.2012.02.007ifetime incremental cost-effectiveness ratio for expanded versus pre-
xpansion screening was about $11,560 per QALY. The results re-
ained robust to both deterministic and probabilistic sensitivity
nalyses. Conclusions: Expanded newborn screening does result in
dditional expenses to the payer, but it also improves patient outcomes
y preventing avoidable morbidity and mortality. The screened popu-
ation benefits from greater QALYs as compared with the unscreened
opulation. Overall, expanded newborn screening in Texas was esti-
ated to be a cost-effective option as compared with unexpanded
ewborn screening.
eywords: children, cost-effectiveness analysis, health economics
ethods, model, quality-adjusted life-years.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Background
Newborn screening involves laboratory analysis of blood samples
from newborns to detect inborn errors of metabolism and allows
timely diagnosis of serious and life-threatening conditions.
Screening should be conducted in the first week of a baby’s life to
ensure treatment initiation before the age of 4 weeks. Timely
treatment helps prevent irreversible mental retardation, physical
disability, and death in most cases [1]. Newborn screening started
in the United States in early 1960s when Dr. Robert Guthrie devel-
oped a bacterial inhibition assay for identifying infants with phe-
nylketonuria (PKU). His technique of collecting blood samples on
filter paper made it possible to implement PKU screening at the
population level [2]. Gradually, more disorders were added to the
ewborn screening panel.
The use of tandem mass spectrometry (MS/MS) has made it
possible to screen for as many as 50 disorders by using the same
blood specimen. With the ability to screen for more disorders,
most US states expanded their newborn screening panel although
the expansion process varied greatly across states. The economic
viability of these expansions has been studied by many research-
ers. In 2002, Schoen and Baker [3] reported that screening for mul-
iple disorders with MS/MS yields an incremental cost-effective-
ess ratio (ICER) of $5827 per quality-adjusted life-year (QALY). Of
he newly added conditions, medium-chain acyl-CoA dehydroge-
ase deficiency (MCADD) is the most common, affecting about 1 in
* Address correspondence to: Simrandeep K. Tiwana, 136 Royal Ro
E-mail: simran.k.tiwana@gmail.com.
† This study was completed while the author was at the Unive
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.20,000 of all newborns in the country. A few studies have been
based on the cost-effectiveness of this condition alone. Insinga et
al. [4], Venditti et al. [5], and Tran et al. [6] reported that universal
screening for MCADD by using MS/MS is a cost-effective option.
Two studies based in California focused on MCADD and several
other conditions and reported that MS/MS screening is a cost-
effective strategy for most conditions, except congenital adrenal
hyperplasia or galactosemia [7,8]. A Canadian study assessed the
expansion of the existing screening system in Ontario and con-
cluded that the average cost of screening for PKU plus 14 other
disorders is Can $95,000 per life-year gained [9]. It is important to
note that in each of the studies, comparisons may differ. Reasons
for this include differences in the base case, patient population,
and number of disorders already being screened, and measures of
cost-effectiveness used. Such differences will automatically im-
pact the results of an economic analysis that is always relative to
the baseline comparator.
The newborn screening panel in Texas was expanded when
House Bill 790 mandated that the state should offer screening for
at least 28 conditions recommended by the American College of
Medical Genetics [10]. In 2007, Texas began to screen for 27 of the
29 recommended conditions. This was a large increase from the 7
disorders that were included in the panel prior to this expansion.
Texas performs two screens on newborns by using separate blood
samples obtained at the ages of 24 to 48 hours and 7 to 14 days,
respectively. Blood samples from infants who test positive after
the second screen need to be sent for confirmatory testing.
dmonton, Alberta, Canada.
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The main objective of this study was to report the incidence of
various newborn screening disorders for the 2007 birth cohort in
Texas and to estimate the cost-effectiveness of the expanded
newborn screening by using Texas-specific data.
Methods
Overview
We developed a cost-effectiveness Markov model by using Tree-
Age to represent the screening outcomes and the sequelae en-
countered by children who are diagnosed with one of the meta-
bolic disorders that are included in the expanded newborn
screening panel of Texas. Because of lack of sufficient information
on incidence and sequelae, we could include only the following
disorders in our analysis: arginosuccinic acidemia (ASA), citrul-
linemia (CIT), homocystinuria (HCY), maple syrup urine disease,
MCADD, glutaric acidemia type I (GA-I), and classical organic acid
disorders (COAD) (including methylmalonic acidemia, propionic
academia, and isovaleric acidemia). One or more disorders were
grouped together if they shared physiological similarities. The
model included a hypothetical cohort of infants born in Texas in
2007, since newborn screening was expanded in January of that
year. We adopted the perspective of the payers in Texas and dis-
counted the costs and QALYs at a base rate of 3%.
Model assumptions
The following assumptions were used while conducting the cost-
effectiveness analysis:
1. A child can have only one metabolic disorder.
2. Testing is timely (specimens obtained within 24–48 hours for first
screen and within 7–14 days for second screen), and testing meth-
ods are appropriate (i.e., with high sensitivity and specificity).
. MS/MS is used for screening for the disorders included in this
study.
. In an individual experiencing more than one sequela, disutility
caused by the most debilitating sequela also includes the dis-
utility caused by other, less debilitating comorbidities.
. Newborn screening in Texas is universal.
Cycle length, termination condition, and discounting
Each cycle length was 1 year. Half-cycle corrections were used for
initial values of recurring costs such as the costs of special diet and
medications. One-time costs incurred in the first year of life, such as
the costs of screening and diagnostic testing, however, were not sub-
ject to half-cycle correction. A discount rate of 3% was used, and all
costs were adjusted to 2007 USD. The Markov model was terminated
when 99.99% of the cohort had entered the “dead” state.
Model structure
As shown in Figure 1, the model structure included two main
branches, one each for the expanded and the unexpanded screen-
ing programs. Subbranches representing six disorder categories
(based on common physiological characteristics) and the healthy
state were used to compare the two scenarios. An infant could
either be affected with one of the screened disorders or be healthy.
A large majority of healthy infants should have a negative screen
result, while some may have a false-positive screen result (posi-
tive screen results that come out negative after confirmatory test-
ing). Because the sensitivity of screening via MS/MS is close to 1.0,
we chose not to include a branch for false-negative results. Figure
2 shows an example of a disease-specific subtree for HCY. HCY isan enzyme deficiency disorder that may be grouped with other
urea cycle disorders. Because of some unique sequelae of this dis-
order, it was analyzed as a separate condition. Accumulation of ho-
mocystine may cause mental retardation, lens abnormalities, and
skeletal abnormalities. Lens abnormalities can be corrected, and so
occur in only one cycle of the structure. Premature death may occur
because of thromboembolism (blood clot formation). Treatment for
HCY includes restricted diet and B6, B12, and betaine supplementa-
tion. In addition, treatment may include cystine in some cases.
Markov states
A healthy infant could either test negative (which is true in most
cases) or test false positive. In the event of a false-positive screen,
the infant would have to undergo confirmatory testing. The model
accounts for the cost and disutility associated with a false-positive
screen in the first year of life. Once it is confirmed that the infant
does not have the suspected disorder, there is no more costs or
disutility allocated to a false-positive case.
True-positive cases would incur the cost and disutility associ-
ated with confirmatory testing in the first year of life, as well as
treatment costs and loss of quality of life because of their condi-
tion for the rest of their lives.
All individuals in the hypothetical cohort were exposed to the risk
of “all-cause mortality,” which estimates the average risk of death,
based on age and sex, by using US Census estimates. Those with one
of the conditions included in the newborn screening panel had an
additional risk of dying from their disease. This approach was used to
ensure a more realistic estimate of the effect of screening.
Event probabilities
The probability of testing positive for any one of the disorders was
equal to the prevalence of that particular disorder. The model
Fig. 1 – ASA, arginosuccinic acidemia; CIT, citrullinemia;
COAD, classical organic acid disorders; GA-1, glutaric
acidemia type I; HCY, homocystinuria; MCADD, medium
chain acyl-CoA dehydrogenase deficiency; MSUD, maple
syrup urine disease; P_disorder name, probability of
disorder.structure for the unexpanded screening was very similar to that for
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615V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 1 3 – 6 2 1expanded screening. In the absence of screening, however, pa-
tients would be diagnosed via clinical symptoms. Table 1 shows
he actual incidence data for 2007 obtained from the Texas Depart-
ent of State Health Services. Estimates from the literature and
xpert opinion were used to reflect different event probabilities in
creened and unscreened patients (where in the absence of
creening, the infant may experience delayed diagnosis and a
igher probability of morbidity and mortality). While it may be
rgued that screening can increase the possibility of diagnosis,
specially among those with milder forms of a condition, there is
nsufficient data to allocate different prevalence to the screened
ersus unscreened populations of the same condition. The only
xception is MCADD where on the basis of recently published ev-
dence, we were able to allocate different probability of testing
ositive to screened and unscreened cohorts. The estimated prob-
bilities of various events associated with both the expanded and
nexpanded branches are listed in Table 2.
Costs
The study included all direct medical costs incurred during the
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cost; Eff, effectiveness; WithScr, with screening; LD, lens dis
neurological damage; DD, developmental delay.screening and treatment of cases. Specific categories include costof screening, cost of confirmatory testing, cost of false-positive
result, cost of disease management (e.g., special diet, medications,
emergency room visits, and inpatient stay), and cost of specific
sequelae (e.g., mental retardation, neurological damage, develop-
mental delay, lens dislocation, spinal osteoporosis, chronic renal
failure, and liver damage). The total cost of screening includes the
cost of the first and second screens and the cost of confirmatory
testing. The total fee charged by the Texas Department of State
Health Services for the first and second screens was used as a
proxy for the cost of screening. The fees charged by the Baylor
Metabolic Institute for confirmatory testing were used as a
proxy for the cost of confirmatory testing. Detailed estimates of
costs of confirmatory testing are shown in Table 3. Although
this study specifically addressed the perspective of third-party
payers in Texas, in the absence of Texas-specific costs, US na-
tional averages were used for estimating the costs of various
sequelae. All costs were adjusted to reflect values in 2007 USD
by using the medical care component of the consumer price
index (http://www.bls.gov/cpi/cpi_dr.htm#2007; accessed May
13, 2010). Detailed estimates of cost inputs used in the model are
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Various aspects of screening and disease management can lead to
short- and long-term loss in quality of life. We included utility
estimates for false-positive screen results, dietary treatment, and
disease-related sequelae (e.g., mental retardation, neurological
damage, developmental delay, liver disease, chronic renal failure,
and spinal osteoporosis). These estimates were obtained from the
literature. Detailed estimates of quality-of-life inputs used in the
model are presented in Table 5.
Table 1 – Incidence of various disorders (detected via MS/M
Disorder Expected incidence
for 400,000 births
Total cases
in 2007
ASA and CIT 5 3
Homocystinuria 2 3
MSUD 2 1
MCADD and other fatty acid
disorders (VLCAD and
LCHAD)
27 30
GA-1 13 7
MMA, PA, IVA (COAD) 3 4
Total 56 48
ASA, arginosuccinic acidemia; CIT, citrullinemia; COAD, classical orga
LHCAD, long-chain hydroxyacyl-CoA dehydrogenase deficiency; MCA
lonic acidemia; MS/MS, tandem mass spectrometry; MSUD, maple syr
A dehydrogenase deficiency.
Table 2 – Probability of events.
Variable
ASA and CIT Incidence in Texas (2007)
Probability of mental retardation
Probability of death
HCY Incidence in Texas (2007)
Probability of lens dislocation
Probability of mental retardation
Probability of spinal osteoporosis
Probability of death
MSUD Incidence in Texas (2007)
Probability of developmental
delay
Probability of neurological
damage
Probability of death
MCADD Incidence in Texas (2007)
Probability of developmental
delay
Probability of death
GA-I Incidence in Texas (2007)
Probability of neurological
damage
Probability of death
COAD Incidence in Texas (2007)
Probability of neurological
damage
Probability of chronic renal failure
Probability of death
Screening Probability of false positive
ASA, arginosuccinic acidemia; CIT, citrullinemia; COAD, classical or
glutaric acidemia type I; HCY, homocystinuria; MCADD, medium chain acyResults
Table 6 shows the lifetime estimates of cost and effectiveness
(with and without screening) for each expanded disorder category.
For HCY, screening was the dominant strategy compared with not
screening. For ASA and CIT, screening resulted in an estimated
ICER of about $10,000 per QALY, which is higher than that for other
disorders included in the analysis. For all the other disorder cate-
gories, screening resulted in an ICER of approximately $4000 or
Texas in 2007.
ales
(n)
Males
(n)
White
(n)
Hispanic
(n)
Asian
(n)
African American
(n)
2 1 1 1 1 0
2 1 0 3 0 0
1 0 0 1 0 0
13 17 19 9 0 2
4 3 3 3 0 1
3 1 3 1 0 0
25 23 26 18 1 3
cid disorders; GA-1, glutaric acidemia type I; IVA, isovaleric acidemia;
edium chain acyl-CoA dehydrogenase deficiency; MMA, methylma-
ine disease; PA, propionic academia; VLCAD, very-long-chain acyl-Co
screening
(range)
Without screening
(range)
Reference
in 130,000 1 in 130,000 DSHS
(0.16–0.24) 0.20 (0.16–0.24) [11]
(0.48–0.73) 0.80 (0.64–0.97) [11]
in 130,000 1 in 130,000 DSHS
(0–0.10) 0.70 (0.57–0.85) [11–13]
(0–0.18) 0.89 (0.79–0.99) [11–13]
(0–0.10) 0.50 (0.35–0.67) [11–13]
(0–0.20) 0.14 (0.04–0.24) [11–13]
in 400,000 1 in 400,000 DSHS
(0.018–0.026) 0.06 (0.045–0.075) [14]
(0.075–0.125) 0.1 (0.075–0.125) [14]
(0.045–0.075) 0.90 (0.80–1.0) [14]
in 25,000 1 in 10,000 DSHS, [15]
(0.03–0.06) 0.08 (0.06–0.10) [16]
(0.037–0.045) 0.25 (0.225–0.275) [16]
in 57,000 1 in 57,000 DSHS
(0.32–0.39) 0.90 (0.72–0.99) [11,17,18]
(0.045–0.056) 0.32 (0.29–0.35) [11,17,18]
in 100,000 DSHS
(0.25–0.30) 0.73 (0.66–0.81) [11,19]
(0.045–0.055) 0.41 (0.37–0.45) [11,19]
(0.10–0.12) 0.50 (0.45–0.55) [11,19]
(0.018–0.022) 0.0175 (0.010–0.019) DSHS
acid disorders; DSHS, Department of State Health Services; GA-1,S) in
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1
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0.05
0.09
0.05
0.10
1
0.022
0.1
0.06
1
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0.05
0.11
0.020
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617V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 1 3 – 6 2 1less per QALY. The overall ICER for expanded versus preexpansion
screening was about $11,560 per QALY at the base discount rate of
3% (Table 7).
The tornado diagram in Figure 3 shows the impact of the most
influential variables on the results of the cost-effectiveness anal-
ysis. The utility of being on treatment without additional com-
plications was the most influential variable, followed by yearly
cost of carnitine supplementation. Among other important
variables were probability of death due to ASA and CIT, with and
without screening; cost of false-positive screen; and cost of spe-
cial diet.
Results of probabilistic sensitivity analysis
Figure 4 shows the cost-effectiveness scatter plot obtained with a
probabilistic sensitivity analysis using a discount rate of 3% for
costs and QALYs. The mean cost for expanded screening was
$115.79 (SD  $2.0; range  $108.96–$122.99). Mean effectiveness
Table 3 – Cost of screening and confirmatory testing in Tex
Disorder name Confirmatory test(s) Current
procedural
terminology
code
Arginosuccinic aciduria/
citrullinemia
Plasma amino acids 82139
Supplemental newborn
screening
83788
Urine organic acids 83918
Homocystinurea Homocystine total 83090
Plasma amino acids 82139
Supplemental newborn
screening
83788
Maple syrup urine
disease
Plasma amino acids 82139
Supplemental newborn
screening
83788
Urine organic acids 83918
MCADD and other fatty
acid disorders
Acylcarnitine profile 82017
Carnitine levels 82379
MCADD DNA analysis 83890
MCADD unknown
mutation
83890
MCADD panel of 8
mutations
83890
Mitochondrial beta
oxidation
88233
Supplemental newborn
screening
83788
Urine organic acids 83918
Glutaric acidemia type I Acylcarnitine profile 82017
Supplemental newborn
screening
83788
Urine organic acids 83918
Isovaleric acidemia Acylcarnitine profile 82017
Supplemental newborn
screening
83788
Urine organic acids 83918
Methylmalonic acidemia/
propionic acidemia
Acylcarnitine profile 82017
Carnitine levels 82379
Supplemental newborn
screening
83788
Urine organic acids 83918
Source. Institute of Metabolic Disease at Baylor Research Institute (h
MCADD, medium chain acyl-CoA dehydrogenase deficiency.
* Texas screens all newborns twice. The total cost of screening was $
† Assuming most cases of MCADD would need basic confirmatory teor expanded screening was 29.921 QALYs (SD  0.0008 QALYs;ange  29.9195–29.9241 QALYs). For preexpansion screening,
ean cost was $83.10 (SD  $1.68; range  $77.09–$89.43) and
ean effectiveness was 29.9190 QALYs (SD  0.00611 QALYs;
ange  29.9172–29.9208 QALYs). Most of the data points (97.5%)
for expanded screening were at or below a cost of $119.74 and
below an effectiveness of 29.9233 QALYs. For preexpansion
screening, 97.5% of the data points were at or below a cost of $86.39
and below an effectiveness of 29.92083 QALYs.
Discussion
As shown by the results of this analysis, expanded screening may
cost an additional $11,560 per QALY at the base discount rate of
3%. Although the absolute difference in the effectiveness of the
two strategies at a population level is relatively small, at 0.002829
QALYs, it can potentially make a significant difference for the in-
r 2007*.
timated
ost ($)
Total cost of
confirmatory
testing per
case ($)
False-positive
cases in 2007
Estimated cost of
confirmatory
testing for false-
positive cases ($)
140 370 45 16,650
35
195
45 220 205 45,100
140
35
140 370 79 29,230
35
195
110 400† 474 189,600
80
150
2000
850
750
35
195
110 340 93 31,620
35
195
110 340 170 57,800
35
195
110 420 42 17,640
80
35
195
ww.baylorhealth.edu/imd/disease.htm).
fore the expansion and $59 after the expansion.
and not the more extensive DNA or mutation analysis.as fo
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39 befants detected with one of the disorders. For most of the disorders,
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618 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 1 3 – 6 2 1expanded screening is associated with more costs coupled with
greater quality of life.
For ASA and CIT, screening costs an estimated additional
$10,000 per QALY at the base rate of 3%, which is likely due to the
higher cost of treatment for these disorders. Although screening
results in higher survival among patients with ASA and CIT, rates
of mental retardation tend to remain high among the survivors,
resulting in poor quality of life for survivors. For HCY, screening
not only costs less due to lower treatment costs but also results in
greater quality of life due to the reduced likelihood of adverse
outcomes in the screened group. A vast majority of the un-
screened patients are at the risk of lens dislocation and chronic
skeletal abnormalities as they grow older, leading to significant
direct medical costs and reduced quality of life. In contrast, only a
few of the screened patients run the risk of lens dislocation or
spinal osteoporosis. Therefore, screening is the dominant strategy
for HCY. For maple syrup urine disease, there is a stark contrast in
the QALYs for screened versus unscreened patients. This can be
explained by the extremely high mortality (which translates to
zero QALYs) in the first two years of life for children who may be
diagnosed late. Screening for GA-I also results in a substantial
increase in QALYs, while still remaining cost-effective. The ICER of
screening and treatment for MCADD is about $633 per QALY,
which is lower than some of the published estimates [4]. Possible
reasons for this difference could be the use of different model
inputs. Furthermore, the treatment plan for cases of MCADD diag-
Table 4 – Treatment costs (in 2007 USD).
Variable description Estimated ave
cost ($)
Yearly cost of carnitine supplements for MCADD 6,600
Yearly cost of chronic renal failure 9023
Yearly cost of developmental delay 5,670
Yearly cost of special diet for metabolic disorders 4,360
Yearly cost of emergency room visits for MCADD
patients*
500
Yearly cost of inpatient stay for MCADD patients* 2,500
One-time cost of lens dislocation 3,085
Yearly cost of ASA and CIT medications 35,780
Yearly cost of medications for homocystinuria 5,000
Yearly cost of COAD medications 1,500
Yearly cost of mental retardation 5,635
Yearly cost of neurological disorders 3,891
Yearly cost of spinal osteoporosis 434.00
One-time average cost of resolving a false-positive
screen, inclusive of repeat screens,
confirmatory testing, and other expenses
1,000
ASA, arginosuccinic acidemia; CIT, citrullinemia; COAD, classical o
deficiency.
* We used frequency of emergency room visits and hospitalizations f
Table 5 – Utility estimates.
Variable name Description
U_CRF Utility of having chronic renal failure
U_FP Utility of receiving a false-positive screen resu
U_LT Utility of liver transplant
U_MR Utility of mental retardation
U_DD Utility of developmental delay
U_ND Utility of neurological damage
U_SLD Utility of severe liver disease
U_SO Utility of spinal osteoporosis
U_TX Utility of being on treatment without complicationsnosed via screening or clinical symptoms would be very similar,
yet QALY improvement in screened cases is significant due to the
reduced risk of mortality. Screening for COAD is also cost-effec-
tive, with the ICER for screened group at about $1800 per QALY.
Timely intervention is crucial in this group of disorders, and pa-
tients can potentially have a better quality of life without incurring
extremely high treatment costs.
Results of the one-way sensitivity analyses point to several
variables that may impact the results of the cost-effectiveness
analysis. Study results were sensitive to variations in discount rate
because it impacts all the costs and utilities after the first year of
life. Within the cost category, cost of false positives and cost asso-
ciated with special diet were the most influential variables. If the
cost of ruling out false-positive screens is very high, it can poten-
tially impact the cost-effectiveness of the program. The cost of
special diet impacts every child who tests positive for any of the
disorders and is placed on a special diet. The cost of carnitine
supplementation is also an important variable in the cost cate-
gory. Although there is no evidence-based recommendation for
carnitine supplementation in patients with MCADD, according to
expert opinion, carnitine supplementation is frequently recom-
mended, especially in the United States (this practice may not be
followed in European countries) [30,31]. In our model, we included
the cost of carnitine supplementation for patients with complica-
tions related to MCADD [30,31]. Because MCADD is the most prev-
alent condition included here, cost of carnitine can affect a signif-
Lower estimate
of cost ($)
Higher estimate
of cost ($)
Reference
6,000 7,200 [9]
7,735 9,797 [20], estimate
5,300 6,400 [21]
4,000 4,800 [9]
400 600 [4,5,21–23,32]
2,000 3,000 [4,5,21–23,32]
2,683 3,353 [24]
32,000 40,000 [9]
4,000 6,000 [9]
1,200 1,800 [9]
4,025 6,708 [25]
2,683 5,098 [25]
325.00 542.00 [26]
800 1,200 Expert opinion, estimate
c acid disorders; MCADD, medium chain acyl-CoA dehydrogenase
ustralian studies and then multiplied those with US cost estimates.
Estimated average utility Range Reference
0.67 0.58–0.74 [19]
0.97 0.95–0.99 [5]
0.67 0.58–0.74 [27]
0.79 0.59–0.84 [28]
0.843 0.792–0.881 [29]
0.84 0.70–0.85 [28]
0.20 0.10–0.3 [27]
0.92 0.88–0.94 [24]rage
rganilt0.90 0.85–0.95 [5]
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category, a significant decline in the probability of death due to
some disorders is seen for the screened versus unscreened popu-
lations. A decline in mortality is the only major difference between
the screened and unscreened patients when other sequelae do
not differ much despite screening. This may explain the influ-
ence of probability of death for ASA and CIT as an influential
variable in this category. The probability of neurological dam-
age also differs significantly for the screened versus unscreened
populations of patients with GA-I and patients with COAD. So,
these variables also impact the overall study results. For the
categories of utility values used in the Markov model, the utility
of being on treatment (with special diet) without any additional
complications impacts most of the members of the cohort. Con-
sequently, this variable is influential as shown by the tornado
diagram.
Results of the overall cost-effectiveness analysis are somewhat
comparable with the results of other studies done in the past.
Other studies may differ in terms of the comparators included,
perspective of analysis, costing year, and country. For example,
the base-case results of the current study show that the ICER for
expanded screening was approximately $11,560 per QALY at a dis-
count rate of 3%. In their 2002 study, Schoen and Baker [3] reported
their base-case estimate as $5827 per QALY. Their results were
based on estimates of a number of disease states, including PKU.
While the current study includes cost-effectiveness estimates of
screening for most of the disorder categories used by Schoen and
Baker, it does not include cost and effectiveness analyses for PKU.
Inclusion of PKU may have changed the results of the study be-
cause it is a much more prevalent condition as compared with
many other disorders. Similarly, the current study differs from the
analysis by Carroll and Downs [7] in terms of the disorders in-
cluded and the utility estimates for sequelae. The current study
results of $11,560 per QALY are also higher than the cost-effective-
ness estimate provided by Feuchtbaum and Cunningham [8]. Ac-
cording to their estimates, screening cost $1628 per QALY in the
base-case estimate. Instead of allocating separate costs to each of
the disease sequelae, they had used an average estimate of $1
million for the cost of lifetime treatment and follow-up. Their es-
timate was derived from a research article based on a Centers for
Table 6 – Average cost and effectiveness by disorder at 3%
With screening
Cost ($) Effectiveness
ASA_CIT 681,455.00 14.34
HCY 267,699.00 24.09
MSUD 136,607.00 25.03
MCADD 266,711.00 24.56
GA-I 291,269.00 24.73
COAD 184,436.00 23.46
ASA, arginosuccinic acidemia; CIT, citrullinemia; COAD, classical org
ICER, incremental cost-effectiveness ratio; MCADD, medium chain
QALYs, quality-adjusted life-years.
Table 7 – Results of overall cost-effectiveness analysis at 3
Strategy Cost ($) Incremental
cost ($)
Ef
Preexpansion screening 83.08897
Expanded screening 115.7953 32.70637C, cost; E, effectiveness; ICER, incremental cost-effectiveness ratio; QALY,Disease Control and Prevention report published in 2003 [25]. The
source article, however, elaborates that most of the costs in this
$1-million estimate are based on the productivity loss due to lost
wages and early mortality. The current study does not include
productivity losses incurred either by the parents or by the pa-
tients (after they reach adulthood), which may be different than
some other studies conducted in the United States. If indirect costs
were included in the present study, the results may be more com-
parable to the conclusions of Feuchtbaum and Cunningham.
Study results also share some similarities with those of a more
recent study based on the cost-effectiveness of expanding new-
born screening in Ontario, Canada [9] In their study, Cipriano et al.
[9] reported that if MS/MS is used for screening newborns for PKU
along with other metabolic disorders, it would only be cost-effec-
tive to include PKU and 14 other conditions on a combined new-
born screening panel. The inclusion of maple syrup urine disease,
GA-I, COAD, and MCADD and other fatty acid disorders along with
PKU would be cost-effective at less than C$70,000 per life-year
gained. Results of the current study also suggest that screening for
these conditions is cost-effective. There are some key differences,
however, between the current study and the Cipriano study, such
as the use of life-years versus quality-adjusted life-years. Further-
more, the Cipriano study was proposing the expansion of newborn
screening in Ontario. Therefore, they included the disorders in a
stepwise manner where the decision to include each successive
disorder in the panel could be based on incidence, prevalence, and
the availability of effective treatment. While these are valid points
to consider before any expansion of an existing program, they may
not be useful for estimating the cost-effectiveness of an expansion
that has already taken place (such as in the case of Texas), where
it may be more relevant to consider simultaneous inclusion of a
number of disorders.
Study limitations
One of the main limitations of this study is that estimates from the
literature and experts were used instead of actual patient data for
most of the costs, probabilities, and outcomes. Each of the pub-
lished studies has its own inherent limitations, and the screening
program described in a study may be systematically different from
Without screening
Cost ($) Effectiveness ICER ($/QALY)
538,334.00 11.3 9,969.24
333,594.00 21.04 Dominant
36,303.00 5.94 4,001.41
250,678.00 19.84 632.97
217,145.00 19.91 2,977.42
142,468.00 15.02 1,773.90
acid disorders; GA-1, glutaric acidemia type I; HCY, homocystinuria;
CoA dehydrogenase deficiency; MSUD, maple syrup urine disease;
eness Incremental
effectiveness
C/E Incremental C/E
(ICER)
901 2.77713
184 0.002829 3.869928 $11,559.86per
QALY.
anic
acyl-%.
fectiv
29.91
29.92quality-adjusted life-year.
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results are also based on relatively short-term follow-up. For ex-
ample, the hospitalization data for patients with MCADD in Aus-
tralia were reported for only the first four years of life [22]. We
estimated the likelihood of hospitalization for children older
than 4 years. Furthermore, some of the studies have been con-
ducted in specialty clinics or in high-incidence communities.
Results from such studies may not be generalizable to other
health care facilities or to communities where many of the dis-
orders are extremely rare. Expert opinion was used for some of
the sequelae, where data from the literature were unclear or
insufficient, which may cause some subjectivity. There is also
very little information available on the quality-of-life issues re-
lated to dietary treatments.
The current analysis included only a subset of the conditions
that are screened for under the expanded panel. Inclusion of all
the disorders was not feasible because of a lack of sufficient
information on sequelae and other model parameters. Speci-
mens for screening may be drawn from infants between 24 and
72 hours of birth, and results are usually available 5 to 10 days
from birth. Some infants may die before any concrete diagnosis
can be made.
It is important to recognize that because of screening, milder
cases of the disease may also be detected. Outcomes for these
patients will be inherently better than for those who have the
severe form of the same disorder. Inclusion of mildly affected pa-
tients in the cohort may create a positive bias in favor of screening.
On the other hand, when data on unscreened cohorts are used,
they include only the more severe cases because the mild forms of
the disease may go undiagnosed. Their disease prognosis is worse
Fig. 3 – Tornado diagram at expanded screening vs preexpa
citrullinemia; GA-1, glutaric acidemia type I.
Fig. 4 – CE scatter plot. C, cost; E, effectiveness; QALY,
quality-adjusted life-year.because of the severity of their disease, which confounds the ef-
fect of late treatment (as compared with that of screened cohorts
who are likely to receive early treatment).
The model included the fee charged for screening as a proxy for
the cost of screening. Because of lack of sufficient information,
screening costs were considered as a single estimate and were not
apportioned among various disorders. The cost of confirmatory
testing may differ depending on individual laboratory practices
and pricing. Estimates used in this study were obtained directly
from the laboratory that supports the screening program in Texas.
Another limitation was the lack of utility estimates specific to
newborn screening disorders. Although there is literature on con-
ditions such as mental retardation, neurological damage, and re-
nal failure, it is problematic to account for the disutility caused by
individual sequelae when a patient is experiencing more than one
complication. There have been comparisons of the disutility
caused by a false-positive newborn screen result with that of a
false-positive cancer screen. It may be argued that the disutility of
a false-positive cancer screen often pertains to the patient (except
in pediatric patients), whereas most of the emotional trauma of a
false-positive newborn screen is experienced by the infant’s fam-
ily. Last, utility estimates of being on special diet are also poorly
understood.
Significance of this study
Since the expansion of Texas’s screening panel in 2007, this is the
first study to estimate the cost-effectiveness of the newborn
screening program in Texas. Results of the present study capture a
variety of aspects in addition to treatment costs, such as cost es-
timates for laboratory activities (screening and confirmatory test-
ing) and case management activities. The study methodology pro-
vides a compilation of disease prognosis and outcomes data
(based on severity) obtained from a number of recent studies.
Study results may further substantiate the policy decision of ex-
panding newborn screening in Texas, particularly the long-term
disease management aspect of newborn screening. Estimates of
long-term costs, such as cost of special diet, and QALYs may be
useful in future plans regarding patient care and coverage of treat-
ment expenses.
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